<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03865056</url>
  </required_header>
  <id_info>
    <org_study_id>18-6194</org_study_id>
    <nct_id>NCT03865056</nct_id>
  </id_info>
  <brief_title>Therapy With High-flow Oxygen by Nasal Cannula vs Noninvasive Ventilation in Patients With Acute Hypoxemic Respiratory Failure: a Crossover Physiologic Study</brief_title>
  <acronym>THIFON</acronym>
  <official_title>Therapy With High-flow Oxygen by Nasal Cannula vs Noninvasive Ventilation in Patients With Acute Hypoxemic Respiratory Failure: a Crossover Physiologic Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background and rationale: A large multicenter randomized controlled trial demonstrated that&#xD;
      in patients with hypoxemic non-hypercapnic respiratory failure treatment with nasal high flow&#xD;
      oxygen (NHF) resulted in a reduction of the endotracheal intubation rate (38%) compared with&#xD;
      noninvasive ventilation (NIV) delivered by facemask (50%) or with conventional oxygen therapy&#xD;
      (47%), although the difference was not statistically significant. These results could be&#xD;
      potentially explained by the physiological benefits provided by the NHF. However, one of the&#xD;
      surprising findings of this study was that patients randomized to the facemask NIV group had&#xD;
      a similar or even poorer outcome than oxygen alone. Interestingly, an observational study&#xD;
      showed that in patients receiving facemask NIV for acute hypoxemia delivered tidal volumes&#xD;
      were higher than expected (8.1-11.1 ml/kg predicted body weight), suggesting that NIV could&#xD;
      potentially cause ventilator-induced lung injury resulting in worsening respiratory failure.&#xD;
&#xD;
      We, therefore, plan a crossover physiologic study investigating the hypothesis that compared&#xD;
      with NIV the treatment with NHF of patients with acute hypoxemic non-hypercapnic respiratory&#xD;
      failure results in a more homogeneous distribution of tidal volume, and hence less&#xD;
      ventilator-induced lung injury, as measured by electrical impedance tomography (EIT).&#xD;
&#xD;
      Methods: This physiologic study will enroll 20 patients from the ICU at Toronto General&#xD;
      Hospital in one year. Adult patients with acute hypoxemic non cardiogenic respiratory failure&#xD;
      and PaO2:FiO2 ≤ 300 mmHg, respiratory rate &gt; 25 breaths/minute, PaCO2 ≤ 45 mmHg and absence&#xD;
      of clinical history of underlying chronic respiratory failure will be eligible. Patients that&#xD;
      received invasive mechanical ventilation for &gt; 48 hours in the same hospital admission,&#xD;
      requiring immediate intubation, with hemodynamic instability (systolic arterial pressure &lt; 90&#xD;
      mmHg after optimal fluid therapy), with Glasgow Coma Scale &lt; 12, or contraindications to&#xD;
      noninvasive ventilation and tracheostomy, will be excluded. After baseline assessment while&#xD;
      receiving oxygen through facemask or nasal prongs, patients will receive in randomly assigned&#xD;
      order NHF for 20 minutes and NIV for 20 minutes, in a crossover manner. EIT recordings,&#xD;
      diaphragm ultrasound, and collection of blood samples for arterial blood gases will be&#xD;
      performed at the end of each phase.&#xD;
&#xD;
      Data analysis: The primary endpoint is the comparison of the EIT intra-tidal ventilation&#xD;
      index between treatment with NHF and NIV. As secondary endpoints, we will determine whether&#xD;
      NHF, in comparison to NIV, provides respiratory support with lower global inhomogeneity index&#xD;
      (EIT), lower tidal volumes, reduces respiratory muscle effort (respiratory rate and&#xD;
      diaphragmatic ultrasound), and improves gas exchange (oxygen saturation, PaO2:FiO2, PaCO2,&#xD;
      RR).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">March 15, 2019</start_date>
  <completion_date type="Anticipated">March 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the intra-tidal ventilation heterogeneity index</measure>
    <time_frame>2 hours</time_frame>
    <description>the intra-tidal ventilation heterogeneity index (VtHit) assessed by electrical impedance tomography (EIT)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hypoxemia</condition>
  <arm_group>
    <arm_group_label>High-Flow Nasal Cannula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Noninvasive ventilation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optiflow (High-flow Nasal Cannula)</intervention_name>
    <description>Optiflow will be applied for 20 minutes</description>
    <arm_group_label>High-Flow Nasal Cannula</arm_group_label>
    <other_name>Optiflow</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Non-invasive Ventilation</intervention_name>
    <description>non-invasive ventilation will be applied for 20 minutes</description>
    <arm_group_label>Noninvasive ventilation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Hypoxemia defined by a ratio of the partial pressure of arterial oxygen to the&#xD;
             fraction of inspired oxygen (PaO2:FiO2) ≤ 300 while the patient is breathing oxygen&#xD;
             through NHF for at least 15 minutes;&#xD;
&#xD;
          2. Respiratory rate &gt; 25 breaths/minute;&#xD;
&#xD;
          3. Partial pressure of arterial carbon dioxide (PaCO2) ≤ 45 mmHg;&#xD;
&#xD;
          4. Absence of clinical history of underlying chronic respiratory failure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Lack of consent;&#xD;
&#xD;
          2. Age &lt; 18 years;&#xD;
&#xD;
          3. Invasive mechanical ventilation for &gt; 48 hours in the same hospital admission&#xD;
&#xD;
          4. Immediate need for intubation;&#xD;
&#xD;
          5. Previous inclusion in the present study;&#xD;
&#xD;
          6. Systolic arterial pressure &lt; 90 mmHg after optimal fluid therapy;&#xD;
&#xD;
          7. Cardiogenic pulmonary edema;&#xD;
&#xD;
          8. Glasgow Coma Scale &lt; 12;&#xD;
&#xD;
          9. Imminent death;&#xD;
&#xD;
         10. Contraindications to noninvasive ventilation;&#xD;
&#xD;
         11. Tracheostomy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>L:orenzo Del Sorbo, MD</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>8009</phone_ext>
    <email>lorenzo.delsorbo@uhn.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Felicity Backhouse, MSc</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>6056</phone_ext>
    <email>felicity.backhouse@uhn.ca</email>
  </overall_contact_backup>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 5, 2019</study_first_submitted>
  <study_first_submitted_qc>March 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2019</study_first_posted>
  <last_update_submitted>March 5, 2019</last_update_submitted>
  <last_update_submitted_qc>March 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

